What is Acadia Pharmaceuticals's stock-based comp?

Acadia Pharmaceuticals (ACAD) reported stock-based comp of $14.7M in Q1 2026.

How has Acadia Pharmaceuticals's stock-based comp changed year-over-year?

Acadia Pharmaceuticals's stock-based comp increased by 29.2% year-over-year, from $11.38M to $14.7M.

What is the long-term trend for Acadia Pharmaceuticals's stock-based comp?

Over 4 years (2021 to 2025), Acadia Pharmaceuticals's stock-based comp has grown at a -4.9% compound annual growth rate (CAGR), from $63.62M to $52.14M.

Acadia Pharmaceuticals ACAD Stock-Based Comp

Stock-Based Comp at other companies

BiogenBIIB

——

Neurocrine BiosciencesNBIX

——

BioCryst PharmaceuticalsBCRX

——

Jazz PharmaceuticalsJAZZ

——

Supernus PharmaceuticalsSUPN

——

Other financials

Income statement

See full

Revenue$268.1M+9.7%

Gross profit$243.3M+8.6%

Operating income-$4.6M-124%

Net income$3.6M-80.8%

EPS (diluted)$0.02-81.8%

Balance sheet

See full

Cash & equivalents$282.2M+29.6%

Total debt$50.8M-9.3%

Total equity$1.2B+63.1%

Total assets$1.6B+41.8%

Cash flow

See full

Operating cash flow$34.0M+67.2%

CapEx$5.2M—

Free cash flow$28.8M+41.6%

Valuation

See full

Market cap$3.87B+37.0%

Profitability

See full

Gross margin91.5%-0.6pp

Operating margin7.4%-16.2pp

Net margin34.3%+11.3pp

FCF margin18.9%—

Returns & leverage

See full

Return on equity37.3%+0.1pp

Debt / equity0×0.0×

Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Acadia Pharmaceuticals's stock-based comp?: Acadia Pharmaceuticals (ACAD) reported stock-based comp of $14.7M in Q1 2026.
How has Acadia Pharmaceuticals's stock-based comp changed year-over-year?: Acadia Pharmaceuticals's stock-based comp increased by 29.2% year-over-year, from $11.38M to $14.7M.
What is the long-term trend for Acadia Pharmaceuticals's stock-based comp?: Over 4 years (2021 to 2025), Acadia Pharmaceuticals's stock-based comp has grown at a -4.9% compound annual growth rate (CAGR), from $63.62M to $52.14M.